PURPOSE/ OBJECTIVES: To test the content validity of a 16-item version of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20). . RESEARCH APPROACH: Cross-sectional, prospective, qualitative design. . SETTING: Six outpatient oncology clinics within the University of Michigan Health System's comprehensive cancer center in Ann Arbor. . PARTICIPANTS: 25 adults with multiple myeloma or breast, gynecologic, gastrointestinal, or head and neck malignancies experiencing peripheral neuropathy caused by neurotoxic chemotherapy. . METHODOLOGIC APPROACH: Cognitive interviewing methodology was used to evaluate the content validity of a 16-item version of the QLQ-CIPN20 instrument. . FINDINGS: Minor changes were made to three questions to enhance readability. Twelve questions were revised to define unfamiliar terminology, clarify the location of neuropathy, and emphasize important aspects. One question was deleted because of clinical and conceptual redundancy with other items, as well as concerns regarding generalizability and social desirability. . INTERPRETATION: Cognitive interviewing methodology revealed inconsistencies between patients' understanding and researchers' intent, along with points that required clarification to avoid misunderstanding. . IMPLICATIONS FOR NURSING: Patients' interpretations of the instrument's items were inconsistent with the intended meanings of the questions. One item was dropped and others were revised, resulting in greater consistency in how patients, clinicians, and researchers interpreted the items' meanings and improving the instrument's content validity. Following additional revision and psychometric testing, the QLQ-CIPN20 could evolve into a gold-standard CIPN patient-reported outcome measure.
PURPOSE/ OBJECTIVES: To test the content validity of a 16-item version of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20). . RESEARCH APPROACH: Cross-sectional, prospective, qualitative design. . SETTING: Six outpatient oncology clinics within the University of Michigan Health System's comprehensive cancer center in Ann Arbor. . PARTICIPANTS: 25 adults with multiple myeloma or breast, gynecologic, gastrointestinal, or head and neck malignancies experiencing peripheral neuropathy caused by neurotoxic chemotherapy. . METHODOLOGIC APPROACH: Cognitive interviewing methodology was used to evaluate the content validity of a 16-item version of the QLQ-CIPN20 instrument. . FINDINGS: Minor changes were made to three questions to enhance readability. Twelve questions were revised to define unfamiliar terminology, clarify the location of neuropathy, and emphasize important aspects. One question was deleted because of clinical and conceptual redundancy with other items, as well as concerns regarding generalizability and social desirability. . INTERPRETATION: Cognitive interviewing methodology revealed inconsistencies between patients' understanding and researchers' intent, along with points that required clarification to avoid misunderstanding. . IMPLICATIONS FOR NURSING: Patients' interpretations of the instrument's items were inconsistent with the intended meanings of the questions. One item was dropped and others were revised, resulting in greater consistency in how patients, clinicians, and researchers interpreted the items' meanings and improving the instrument's content validity. Following additional revision and psychometric testing, the QLQ-CIPN20 could evolve into a gold-standard CIPN patient-reported outcome measure.
Authors: Christian Geber; Markus Breimhorst; Berenike Burbach; Christina Egenolf; Bernhard Baier; Marcel Fechir; Juergen Koerber; Rolf-Detlef Treede; Thomas Vogt; Frank Birklein Journal: Pain Date: 2013-08-30 Impact factor: 6.961
Authors: J D England; G S Gronseth; G Franklin; R G Miller; A K Asbury; G T Carter; J A Cohen; M A Fisher; J F Howard; L J Kinsella; N Latov; R A Lewis; P A Low; A J Sumner Journal: Neurology Date: 2005-01-25 Impact factor: 9.910
Authors: Kathleen A Griffith; Ingemar S J Merkies; Elizabeth E Hill; David R Cornblath Journal: J Peripher Nerv Syst Date: 2010-12 Impact factor: 3.494
Authors: Cindy Tofthagen; Kristine A Donovan; Mary Ann Morgan; David Shibata; Yating Yeh Journal: Support Care Cancer Date: 2013-08-01 Impact factor: 3.603
Authors: Charles L Loprinzi; Brandi N Reeves; Shaker R Dakhil; Jeff A Sloan; Sherry L Wolf; Kelli N Burger; Arif Kamal; Nguyet A Le-Lindqwister; Gamini S Soori; Anthony J Jaslowski; Paul J Novotny; Daniel H Lachance Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544
Authors: Debra L Barton; Edward J Wos; Rui Qin; Bassam I Mattar; Nathan Benjamin Green; Keith S Lanier; James Dewitt Bearden; John W Kugler; Kay L Hoff; Pavan S Reddy; Kendrith M Rowland; Mike Riepl; Bradley Christensen; Charles L Loprinzi Journal: Support Care Cancer Date: 2010-05-25 Impact factor: 3.603
Authors: Ellen M Lavoie Smith; Noah Zanville; Grace Kanzawa-Lee; Clare Donohoe; Celia Bridges; Charles Loprinzi; Jennifer Le-Rademacher; James J Yang Journal: Support Care Cancer Date: 2018-11-20 Impact factor: 3.603
Authors: Jennifer S Gewandter; Joanna Brell; Guido Cavaletti; Patrick M Dougherty; Scott Evans; Lynn Howie; Michael P McDermott; Ann O'Mara; A Gordon Smith; Daniela Dastros-Pitei; Lynn R Gauthier; Simon Haroutounian; Matthew Jarpe; Nathaniel P Katz; Charles Loprinzi; Paul Richardson; Ellen M Lavoie-Smith; Patrick Y Wen; Dennis C Turk; Robert H Dworkin; Roy Freeman Journal: Neurology Date: 2018-07-27 Impact factor: 9.910
Authors: Ellen M Lavoie Smith; Tanima Banerjee; James J Yang; Celia M Bridges; Paola Alberti; Jeff A Sloan; Charles Loprinzi Journal: Cancer Nurs Date: 2019 May/Jun Impact factor: 2.592
Authors: Marie Selvy; Nicolas Kerckhove; Bruno Pereira; Fantine Barreau; Daniel Nguyen; Jérôme Busserolles; Fabrice Giraudet; Aurélie Cabrespine; Carine Chaleteix; Martin Soubrier; Jacques-Olivier Bay; Richard Lemal; David Balayssac Journal: Front Pharmacol Date: 2021-04-22 Impact factor: 5.810
Authors: Marie Selvy; Bruno Pereira; Nicolas Kerckhove; Jérôme Busserolles; Fadila Farsi; Virginie Guastella; Patrick Merle; Denis Pezet; David Balayssac Journal: Support Care Cancer Date: 2021-01-05 Impact factor: 3.359
Authors: Kathleen Potempa; Benjaporn Rajataramya; Debra L Barton; Naruemol Singha-Dong; Rob Stephenson; Ellen M L Smith; Matthew Davis; Ivo Dinov; Benjamin M Hampstead; James E Aikens; Laura Saslow; Philip Furspan; Atiya Sarakshetrin; Srijan Pupjain Journal: Health Res Policy Syst Date: 2019-06-14
Authors: Ellen M Lavoie Smith; Robert Knoerl; James J Yang; Grace Kanzawa-Lee; Deborah Lee; Celia M Bridges Journal: Cancer Control Date: 2018 Jan-Mar Impact factor: 3.302